Key result
Melatonin reduces oxidative stress markers and weekly angina episodes vs placebo in stable angina.
Why the study?
The relationship between changes in oxidative stress markers and angina symptom burden and sleep quality in stable angina patients receiving adjunctive melatonin therapy was unclear.
Does melatonin 5 mg once daily improve oxidative biomarkers and angina symptoms in patients with stable angina?
RCT (n=100)
Quadruple blind
Randomized
No
Does melatonin 5 mg once daily improve oxidative biomarkers and angina symptoms in patients with stable angina?
Absolute Event Rate: -1.03% vs -0.21%
p-value: p=<0.001
Adjunctive melatonin therapy in patients with stable angina significantly improves oxidative stress biomarkers, which correlates with reduced angina frequency and improved sleep quality.
Adjunctive melatonin may reduce angina episodes in stable angina; extends oxidative stress biomarker gains to clinical symptom relief.
Objective: To investigate the relationship between change in oxidative stress markers and change in angina symptom burden and sleep quality in patients with stable angina given adjunctive melatonin therapy. Study Design: Randomized, quadruple blind, placebo-controlled StudyPlace and Duration of Study: This study was conducted at the College of Pharmacy, University of Thi-Qar, Iraq from 1st February 2026 to 30th April 2026 Methods: One hundred patients were enrolled, among them 55 patients taking melatonin 5 mg once daily at night and 45 taking placebo, in addition to usual anti-anginal treatment. Oxidative stress markers were malondialdehyde, superoxide dismutase and glutathione. Clinical measures were the number of angina episodes per week, angina severity, short-acting nitrate use, and Pittsburgh Sleep Quality Index. Results: In the melatonin group, malondialdehyde decreased from 4.82±0.91 to 3.79±0.81 μmol/L, while superoxide dismutase increased from 6.21±1.15 to 7.15±1.20 U/mL and glutathione from 38.7±6.5 to 44.8±7.1μmol/L. Weekly angina episodes decreased from 3.4±1.7 to 1.3±1.1, short acting nitrate use from 3.0±1.8 to 1.0±1.1 doses/week, and Pittsburgh Sleep Quality Index from 9.1±3.0 to 6.2±2.7. Conclusion: Favourable changes in oxidative stress biomarkers, particularly reduced malondialdehyde and increased glutathione, were associated with improved angina symptoms and sleep quality.
No takes yet. Share an insight, caveat, or question.
Hadi et al. (2026) conducted an RCT in Stable angina (n=100). Melatonin vs. Placebo was evaluated on Mean change in malondialdehyde (MDA) at 8 weeks (p=<0.001). Melatonin 5 mg daily significantly reduced malondialdehyde levels (mean change -1.03 vs -0.21 µmol/L) and weekly angina episodes compared to placebo in patients with stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: